Effects of ascorbate on leucocytes: Part IV. Increased neutrophil function and clinical improvement after oral ascorbate in 2 patients with chronic granulomatous disease.
A brother and sister with chronic granulomatous disease (CGD) of the autosomal recessive type, and with markedly defective neutrophil motility and elevated serum IgE levels, were treated with a single oral daily dose of 1 g ascorbate for 6 months. Neutrophil function and serum IgE levels were measured repeatedly at approximately monthly intervals. Both children also received prophylactic antibiotics which were always stopped 1 week prior to testing of immune function. Ascorbate treatment was accompanied by significantly increased neutrophil motility and post-phagocytic metabolic activity, and a reduction in serum IgE levels. Enhanced neutrophil function correlated with clinical improvement. Both children have remained free of infection since ascorbate was added to their regimen and have gained weight.
D001205:Ascorbic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D001798:Blood Proteins / Q000032:analysis; D002465:Cell Movement / Q000187:drug effects; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D006105:Granulomatous Disease, Chronic / Q000188:drug therapy / Q000378:metabolism*; D006600:Hexosephosphates / Q000378:metabolism; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis; D007136:Immunoglobulins / Q000032:analysis; D007455:Iodine / Q000097:blood; D008297:Male; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism; D009580:Nitroblue Tetrazolium; D011485:Protein Binding
D001798:Blood Proteins; D006600:Hexosephosphates; D007136:Immunoglobulins; D009580:Nitroblue Tetrazolium; D007073:Immunoglobulin E; D007455:Iodine; D001205:Ascorbic Acid